Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stryker receives subpoena and warning letter

This article was originally published in Clinica

Executive Summary

Orthopaedics firm Stryker has been handed a subpoena by the attorney general of New Jersey, requesting information relating to its financial relationship with physicians participating in certain clinical trials. The Kalamazoo, Michigan-based company is currently working on its response to the subpoena, which it claims has been issued to other major medical device manufacturing companies. Separately, Stryker has received a warning letter from the US FDA in relation to its craniomaxillofacial implant products. Full details of the warning were not disclosed and a spokesperson for the company told Clinica that it would not be making any further comments. Earlier this year, Stryker came under investigation from the US attorney’s office for the district of Massachusetts following claims of illegal and inaccurate promotion of its orthobiological products (see Clinica No 1336, p 3).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel